Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, Moshfeghi DM, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Schmelter T, Leal S, Köfüncü E, Azuma N; FIREFLEYE Study Group. Stahl A, et al. Among authors: chu k. JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564. JAMA. 2022. PMID: 35881122 Free PMC article. Clinical Trial.
An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.
Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA. Do DV, et al. Among authors: chu k. Br J Ophthalmol. 2009 Feb;93(2):144-9. doi: 10.1136/bjo.2008.138271. Br J Ophthalmol. 2009. PMID: 19174400 Clinical Trial.
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA. Nguyen QD, et al. Among authors: chu k. Ophthalmology. 2009 Nov;116(11):2141-8.e1. doi: 10.1016/j.ophtha.2009.04.030. Epub 2009 Aug 22. Ophthalmology. 2009. PMID: 19700196 Clinical Trial.
Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration.
Nguyen QD, Campochiaro PA, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, Do DV, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarbaum J; Clear-It 1 Investigators. Nguyen QD, et al. Among authors: chu k. J Ocul Pharmacol Ther. 2012 Dec;28(6):581-8. doi: 10.1089/jop.2011.0261. Epub 2012 Jul 9. J Ocul Pharmacol Ther. 2012. PMID: 22775078 Clinical Trial.
Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
Heissigerová J, Callanan D, de Smet MD, Srivastava SK, Karkanová M, Garcia-Garcia O, Kadayifcilar S, Ozyazgan Y, Vitti R, Erickson K, Athanikar A, Chu K, Saroj N, Sundaram PA, Varona R, Corp-Dit-Genti V, Buggage R, Cheng Y, Soo Y, Nguyen QD. Heissigerová J, et al. Among authors: chu k. Ophthalmology. 2019 Mar;126(3):428-437. doi: 10.1016/j.ophtha.2018.09.044. Epub 2018 Oct 11. Ophthalmology. 2019. PMID: 30316888 Clinical Trial.
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, Berliner AJ, Chu K, Cheng Y, Boyer DS. Khurana RN, et al. Among authors: chu k. Am J Ophthalmol. 2019 Apr;200:161-168. doi: 10.1016/j.ajo.2019.01.005. Epub 2019 Jan 19. Am J Ophthalmol. 2019. PMID: 30664844 Clinical Trial.
3,110 results